The invention provides compositions, pharmaceutical preparations and methodsfor inhibition of cystic fibrosis transmembrane conductance regulator protein(CFTR) that are useful for the study and treatment of CFTR-mediated diseasesand conditions. The compositions and pharmaceutical preparations of theinvention may comprise one or more thiazolidinone compounds, and mayadditionally comprise one or more pharmaceutically acceptable carriers,excipients and/or adjuvants. The methods of the invention comprise, in certainembodiments, administering to a patient suffering from a CFTR-mediated diseaseor condition, an efficacious amount of a thiazolidinone compound. In otherembodiments the invention provides methods of inhibiting CFTR that comprisecontacting cells in a subject with an effective amount of a thiazolidinonecompound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinonecompound to a non-human animal in an amount sufficient to inhibit CFTR.
